Intravenous (IV) ketamine is not FDA approved for the treatment of depression. The FDA has approved ketamine only as an anesthetic, a use it has held since 1970. A closely related nasal spray called esketamine (brand name Spravato) did receive FDA approval for treatment-resistant depression in 2019, but that approval does not extend to IV ketamine infusions. This distinction has real consequences for how the two are regulated, monitored, and paid for.
What the FDA Has Actually Approved
Ketamine is a Schedule III controlled substance approved by the FDA for induction and maintenance of general anesthesia. That’s it. The FDA has been explicit on this point, stating in a June 2024 communication that “ketamine is not approved for the treatment of any psychiatric disorder,” even as interest in its antidepressant potential has surged.
Esketamine, sold as Spravato, is a purified form of one half of the ketamine molecule (the S-enantiomer). It was approved specifically for adults with treatment-resistant depression, meaning people who haven’t responded to at least two other antidepressants. Esketamine must be given as a nasal spray in a certified healthcare setting under direct observation, through a strict safety program called REMS. So while the two drugs are chemically related, they occupy very different regulatory positions.
Why IV Ketamine Is Still Widely Used
Doctors can legally prescribe FDA-approved drugs for uses beyond their approved indication. This is called off-label prescribing, and it’s common across medicine. Hundreds of ketamine infusion clinics now operate in the United States, offering IV ketamine specifically for depression, typically at doses far lower than those used for anesthesia.
The clinical interest is driven by genuinely striking results. In a double-blind randomized trial comparing ketamine to an active sedative control, 64.8% of patients with treatment-resistant depression responded to a single 40-minute IV infusion, compared to 28% in the control group. Response here means at least a 50% reduction in depression symptoms. An open-label study of repeated infusions (up to six over two weeks) found a response rate of about 71%.
For context, most standard antidepressants take four to six weeks to show benefit, and many patients with treatment-resistant depression have already tried multiple medications without adequate relief. Ketamine can begin working within hours.
How Long the Effects Last
The antidepressant effect of a single ketamine infusion is real but temporary. Early studies suggested relief lasting several days to about one week after one infusion. Among patients who responded to a series of six infusions, the median time to relapse was 18 days after the final dose, though individual results varied widely, from as few as 4 days to more than 83 days. Repeated infusions appear to produce a more durable response than a single session, even after the series ends.
Because the effects fade, most clinics offer an initial series of infusions followed by periodic “booster” sessions. There is no standardized long-term protocol, and longer-term efficacy data remains limited.
How Ketamine Works Differently Than Other Antidepressants
Traditional antidepressants target serotonin, norepinephrine, or dopamine. Ketamine works through an entirely different system. It blocks a receptor involved in glutamate signaling, the brain’s primary excitatory chemical messenger. This blockade triggers a cascade of effects: it boosts the activity of nerve cells in mood-relevant brain regions, promotes the production of proteins involved in forming new neural connections, and activates growth-signaling pathways that strengthen synapses. In short, ketamine appears to help the brain rapidly rebuild connections that depression has weakened, which may explain why its effects emerge so much faster than those of conventional antidepressants.
Safety Concerns and Monitoring
Ketamine is not a benign drug. Common acute effects during infusion include dissociation (a feeling of detachment from your body or surroundings), nausea, dizziness, and temporary increases in blood pressure and heart rate. Some patients experience brief perceptual disturbances or anxiety. These effects typically resolve within one to two hours after the infusion ends.
Professional guidelines recommend that ketamine for depression be administered only in clinical settings with multidisciplinary staff who can monitor vital signs, mood, and cognitive function throughout the session. The FDA has raised particular concern about compounded ketamine products (oral tablets, lozenges, nasal sprays) sold through telehealth platforms for at-home use. In a safety alert, the agency warned that home use removes the protection of onsite monitoring and has been linked to adverse events including respiratory depression. Reported risks across all ketamine formulations include sedation, dissociation, worsening of psychiatric symptoms, abuse potential, blood pressure spikes, breathing problems, and bladder damage with repeated use.
Insurance and Out-of-Pocket Costs
The lack of FDA approval for depression directly affects your wallet. Most commercial and government insurance plans classify IV ketamine for depression as experimental or investigational and do not cover it. Patients typically pay entirely out of pocket, with a single infusion generally costing several hundred dollars and an initial series of six sessions adding up quickly.
Spravato, by contrast, is more likely to be covered because its FDA approval gives insurers a clear basis for reimbursement. Coverage still usually requires prior authorization and documentation that you’ve tried and failed other treatments. The drug is billed through your medical benefit since it must be administered in a clinic, though specifics vary by plan.
Some patients and providers choose IV ketamine despite the cost difference because clinical experience with racemic (full-molecule) ketamine is more extensive, or because a patient responds better to it than to esketamine. Occasional case-by-case insurance exceptions do occur for IV ketamine, but they are not the norm.
The Regulatory Gap
The situation creates an unusual landscape. IV ketamine has a substantial and growing evidence base for depression, with response rates that compare favorably to most psychiatric treatments. A consensus statement published in JAMA Psychiatry acknowledged ketamine’s potential benefit for mood disorders while cautioning that sample sizes have been relatively small, long-term data is limited, and the risks of the drug deserve careful consideration. The authors emphasized an evidence-based approach and patient safety in the absence of formal regulatory guidance.
Because IV ketamine clinics operate in an off-label space, there is no standardized protocol, no required safety program like the one governing Spravato, and no consistent oversight of how clinics screen patients, dose the drug, or monitor outcomes. Quality varies. If you’re considering IV ketamine, look for a clinic staffed by board-certified psychiatrists or anesthesiologists, one that conducts thorough psychiatric evaluations before treatment, monitors vitals during every session, and has a clear plan for integrating ketamine with ongoing mental health care.